comparemela.com
Home
Live Updates
Rare Genetics - Breaking News
Pages:
5
6
7
8
9
10
11
Page 4 - Rare Genetics News Today : Breaking News, Live Updates & Top Stories | Vimarsana
TAK-755 trumps plasma-based therapy, trial shows
Compared to plasma-based therapies, TAK-755 (recombinant ADAMTS13) protein showed strong efficacy in a trial for cTTP, Takeda revealed.
United kingdom
Daniel curran
Marie scully
International society on thrombosis
Rare genetics
Hematology therapeutic area unit
University college london hospitals
International society
Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
OSAKA, Japan & CAMBRIDGE, Mass. (BUSINESS WIRE) Jun 25, 2023
City of
United kingdom
United states
Jun saito
Megan ostrower
Marie scully
Daniel curran
Aj thromb haemost
Van dorland
Kremer hovinga
Little to no plasma exchange
Takeda pharmaceutical company
Royal college of pathologists bulletin
University college london hospitals
Department of haematology
Exchange commission
Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
OSAKA, Japan & CAMBRIDGE, Mass. (BUSINESS WIRE) Jun 25, 2023
City of
United kingdom
United states
Van dorland
Daniel curran
Megan ostrower
Jun saito
Marie scully
Aj thromb haemost
Kremer hovinga
Royal college of pathologists bulletin
Japan ministry of health
University college london hospitals
Exchange commission
Takeda pharmaceutical company
Drug administration
Recombinant ADAMTS13 Replacement Therapy Under Review for Congenital TTP
The FDA has accepted for Priority Review the BLA for TAK-755 for the treatment of congenital thrombotic thrombocytopenic purpura.
Daniel curran
Drug administration
Priority review
Biologics license application
Rare genetics
Hematology therapeutic area unit
Fast track
Orphan drug
Rare pediatric disease
Takeda Pharmaceutical : to Hold Fourth Quarter and Full-Year FY2022 Earnings Call on May 11
Takeda to Hold Fourth Quarter and Full-Year FY2022 Earnings Call on May 11 May 1, 2023 OSAKA, Japan, and. | May 2, 2023
United states
United kingdom
Christophe weber
Brendan jennings
Takeda pharmaceutical company limited
International media
Research development
Exchange commission
Chief executive officer
Chief financial officer
Rare genetics
Plasma derived therapies
Media contacts
Looking statements
Annual report
Takeda pharmaceutical company limited stock exchange
vimarsana © 2020. All Rights Reserved.